EBITDA CAGR: N/A

EBITDA CAGR uses clean operating EBITDA derived from reported operating income plus depreciation and amortization.

Over the past 12 months, EBITDA CAGR is N/A. EBITDA CAGR shows how the company's operating profitability has grown before depreciation and amortization. This reflects the growth of the core business's cash-operating earnings power, independent of capital-intensity and accounting depreciation choices.

MEDS EBITDA CAGR Chart

No data available

MEDS Quarterly EBITDA Growth (YoY)

EBITDA growth vs the same fiscal quarter in the prior fiscal year, last 7 comparable quarters.

EBITDA

MEDS Quarterly EBITDA

$-6.99M

Reported quarterly EBITDA; no daily interpolation. Q2 FY2026 (2026-06-30): $-6.99M.

≈16x over 10Y

EBITDA CAGR History

No historical data available

Quarterly EBITDA: QoQ & YoY

Period	Period End	Value	QoQ Growth	YoY Growth
Q2 FY2026	2026-06-30	-$6.99M	-23.5%	-48.8%
Q1 FY2026	2026-03-31	-$5.66M	+52.8%	+81.5%
Q4 FY2025	2025-12-31	-$12.00M	+61.0%	-286.9%
Q3 FY2025	2025-09-30	-$30.75M	-554.5%	-2283.0%
Q2 FY2025	2025-06-30	-$4.70M	+84.6%	N/A
Q1 FY2025	2025-03-31	-$30.55M	-885.2%	-2901.4%